Keyphrases
Aggressive Lymphoma
80%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
BEAM Regimen
20%
Carmustine
40%
Categorical Variables
20%
Cell Infusion
20%
Cell-to-cell
20%
Chemosensitive
100%
Chemotherapy
20%
Chi-square
20%
Cohort Analysis
20%
Comorbidity
20%
Cumulative Dose
20%
Cytarabine
40%
Diffuse Large B Cell
40%
Disease Status
20%
Documented Infection
20%
Drug Dosing
20%
Efficacy Profile
20%
Elevated Liver Enzymes
20%
Etoposide
40%
Event-free Survival
20%
First Complete Remission
20%
Heavily Pretreated Patients
20%
Hematopoietic Cell Transplantation
100%
Hematotoxicity
20%
High Dose
20%
High Risk
20%
Hodgkin Lymphoma
100%
Israel
20%
June 2013
20%
Less Toxic
20%
Low Incidence
20%
Low Intensity
40%
Low Toxicity
20%
Low-grade Lymphoma
20%
Lymphoma
20%
Lymphoma Patients
100%
Mann-Whitney
20%
Mantle Cell
40%
Matched Cohort Analysis
100%
Median Time
20%
Melphalan
40%
Microbiology
20%
Mucositis
20%
Multiple Comorbidities
20%
Neutrophil Engraftment
20%
Non-Hodgkin Lymphoma
20%
Non-relapse Mortality
20%
Nonhematologic
20%
Nonparametric Test
20%
Overall Survival
40%
Partial Remission
20%
Positive Outcomes
20%
Preparative Regimen
40%
Pretransplant
20%
Progression-free Survival
80%
Renal Disease
20%
Safety Profile
20%
Subgroup Analysis
20%
T-cell Lymphoma
40%
Transplant Center
20%
Treatment Strategy
20%
Treatment Toxicity
40%
Ultra-low Dose
20%
Medicine and Dentistry
Aggressive Lymphoma
57%
B Cell
28%
Carmustine
28%
Cell Transplantation
100%
Cohort Analysis
100%
Conditioning
14%
Cytarabine
28%
Disease
14%
Drug Megadose
14%
Elevated Transaminases
14%
Engraftment
14%
Etoposide
28%
Event Free Survival
14%
Hematopoietic Stem Cell
100%
Hodgkin's Lymphoma
71%
Infection
14%
Infusion
14%
Low Drug Dose
14%
Melphalan
28%
Mucositis
14%
Neutrophil
14%
Non-Hodgkin Lymphoma
28%
Nonparametric Test
14%
Overall Survival
28%
Progression Free Survival
57%
Subgroup Analysis
14%
T-Cell Lymphoma
28%
Transplantation
14%